中文(繁體)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Wiener Klinische Wochenschrift 1976-Sep

[Long-term use of medium chain triglycerides in cystic fibrosis (author's transl)].

只有註冊用戶可以翻譯文章
登陸註冊
鏈接已保存到剪貼板
K Widhalm
M Götz

關鍵詞

抽象

Conventional treatment of 15 children (aged 4 to 17 years) with cystic fibrosis and persistent failure to thrive was supplemented on an out-patient basis by a daily oral intake of 35 g of medium chain triglycerides (MCT) fat. Follow-up investigations were pursued for a longer period than described in the literature, namely up to 6 months after initiation of the MCT diet. While frequency of the bowel movements was reduced and abdominal discomfort disappeared no weight gain was observed. Clinically, steatorrhoea was clearly diminished. Pre-treatment serum cholesterol levels were lower (121 mg/dl, n=25) than in healthy subjects (182.2 mg/dl, n=56). No significant changes in either serum cholesterol or serum triglycerides were detected over the 6-month period. There were no clinical signs of an essential fatty acid deficiency in 4 patients followed up for 2 years so far. MCT fat should be included in the standard dietary regimen used in the management of any child with cystic fibrosis and failure to thrive. Its use is fully justified by the clinical improvement and alleviation of the steatorrhoea.

加入我們的臉書專頁

科學支持的最完整的草藥數據庫

  • 支持55種語言
  • 科學支持的草藥療法
  • 通過圖像識別草藥
  • 交互式GPS地圖-在位置標記草藥(即將推出)
  • 閱讀與您的搜索相關的科學出版物
  • 通過藥效搜索藥草
  • 組織您的興趣並及時了解新聞研究,臨床試驗和專利

輸入症狀或疾病,並閱讀可能有用的草藥,輸入草藥並查看其所針對的疾病和症狀。
*所有信息均基於已發表的科學研究

Google Play badgeApp Store badge